002675 Yantai Dongcheng Biochemicals
- 12.92
- +0.50+4.03%
Yantai Dongcheng Biochemicals News
Yantai Dongcheng Biochemicals (002675.SZ): A new type of dual-target radioactive internal diagnostic drug approved for clinical trials.
Yantai Dongcheng Biochemicals (002675.SZ) announced that its wholly-owned subsidiary, Yantai Lan Na Cheng Biotechnology Co., Ltd. (referred to as...
Dongcheng Pharmaceutical: 2024 Semi-Annual Report
Dongcheng Pharmaceutical: 2024 Semi-Annual Report Summary
Yantai Dongcheng Biochemicals (002675.SZ) announced its performance for the first half of the year, with a net income of 0.112 billion yuan, a decrease of 39.35%.
Yantai Dongcheng Biochemicals (002675.SZ) released the 2024 interim report. During the reporting period, the company achieved revenue...
Yantai Dongcheng Biochemicals (002675.SZ): The net income in the first half of the year was 0.112 billion yuan, a year-on-year decrease of 39.35%.
Yantai Dongcheng Biochemicals (002675.SZ) announced its semi-annual report for the year 2024, during which the company achieved revenue of 1.421 billion yuan, a year-on-year decrease of 20.41%; net income attributable to shareholders of the listed company was 0.112 billion yuan, a year-on-year decrease of 39.35%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.106 billion yuan, a year-on-year decrease of 39.02%; and basic earnings per share were 0.1356 yuan.
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Sheds CN¥396m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Yantai Dongcheng Biochemicals (002675.SZ): Its subsidiary, Lanna Cheng, has obtained the approval notice for drug clinical trials.
On August 2nd, Gelunhui announced that Yantai Dongcheng Biochemicals (referred to as "LanNacheng") a subsidiary of the company, received approval notice from the National Medical Products Administration regarding the clinical trial of 177Lu-LNC1011 injection. The company's research product, 177Lu-LNC1011 injection, is a targeted prostate-specific membrane antigen (Prostate Specific
Is Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Stock Price Struggling As A Result Of Its Mixed Financials?
Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.
It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.
Does Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Have A Healthy Balance Sheet?
Dongcheng Biochemicals' Unit Gets Nod to Register Coronary Artery Disease Drug
Yantai Dongcheng Biochemicals (002675.SZ): Technetium [99mTc] Tiludronate Injection Obtains Market Approval.
Yantai Dongcheng Biochemicals (002675.SZ) has announced that its wholly-owned subsidiary, Nanjing Jiangyuan Andico Electronic Research and Development Co., Ltd. (referred to as "Andico"), has received the approval and issuance of the registration certificate for the pharmaceutical Technetium [99mTc] Tetrofosmin Injection from the National Medical Products Administration. The Technetium [99mTc] Tetrofosmin Injection has been approved for production and sale through a drug marketing authorization application.
Express News | Yantai Dongcheng Says Unit Received "Study May Proceed Letter" From U.S. FDA on Clinical Trials of Lu-Lnc1011 for Prostate Cancer Treatment
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Shareholders Might Be Looking For Exit
Yantai Dongcheng Biochemicals (002675.SZ) equity distribution for 2023: 1.25 yuan per 10 shares.
Yantai Dongcheng Biochemicals (002675.SZ) has announced the equity distribution plan for 2023: based on the existing total share capital of the company, a cash dividend of RMB 1.25 per 10 shares will be distributed to all shareholders. The equity distribution registration date is June 21, 2024 and the ex-dividend date is June 24, 2024.
Yantai Dongcheng Biochemicals (002675.SZ): The operation of Hefei nuclear medicine production center has been put into operation.
Yantai Dongcheng Biochemicals (002675.SZ) announced that the company has received a research and development project from its wholly-owned subsidiary, Nanjing Jiangyuan Andyco Electronic Technology.
Both Retail Investors Who Control a Good Portion of Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Along With Institutions Must Be Dismayed After Last Week's 3.3% Decrease
Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug
Dongcheng Pharmaceutical (002675.SZ): Clinical trial application approved for ¹ Lu-LNC1010 injection
Dongcheng Pharmaceutical (002675.SZ) issued an announcement that the company's holding subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (...
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Analysis
Price Target
No Data
No Data